Alice Raymond1, Andrew Hill2, Anton Pozniak3. 1. Department of Public Health, Imperial College London, London, UK. 2. Molecular and Clinical Pharmacology, Liverpool University, Liverpool, UK. 3. St Stephens Centre, Chelsea and Westminster Hospital, London, UK.
Abstract
INTRODUCTION: Patients on antiretroviral treatment with undetectable HIV RNA levels have a significantly lower risk of clinical disease progression and onward HIV transmission. This study aimed to estimate and compare the percentage of all HIV-positive people who are diagnosed, are linked to care, are taking antiretroviral treatment and have undetectable HIV RNA, in eight European and high-income countries: the United States, the United Kingdom, France, the Netherlands, Denmark, Australia, British Columbia (Canada) and Georgia. MATERIALS AND METHODS: For each country, the number of people in five key stages of the HIV treatment cascade was collected: 1. HIV infected, 2. Known to be HIV positive, 3. Linked to care, 4. Taking antiretroviral treatment, and 5. Having undetectable HIV RNA. Estimates were extracted from national reports (1-3), the UNAIDS database, conference proceedings (4) and peer-reviewed articles (5-7). The quality of the estimates and reporting methods were assessed individually for each country, with selection criteria such as availability of nationwide database and routinely collected data. Treatment cascades were constructed using estimates from 2010 to 2012. RESULTS: As shown in Table 1, the percentage of all infected people with undetectable HIV RNA ranged from 20% in Georgia to 59% in Denmark. Of the high-income countries, the United States has the lowest percentage of individuals with undetectable viral load (25% to median 52%), associated with the highest HIV incidence rate (15.30 per 100,000 to median 6.07 per 100,000). The pattern of the cascades differed between countries: in the United States, there is a fall from 66% to 33% (-33%) between linkage to care and start of antiretroviral treatment. However, in Georgia, the greatest loss in continuum was zat diagnosis, with 48% of undiagnosed HIV-positive individuals. CONCLUSIONS: There are great disparities among European and high-income countries in the percentage of HIV-positive individual with undetectable HIV RNA. Furthermore, the treatment cascades show different key break points, underlying inequalities in HIV care between countries.
INTRODUCTION:Patients on antiretroviral treatment with undetectable HIV RNA levels have a significantly lower risk of clinical disease progression and onward HIV transmission. This study aimed to estimate and compare the percentage of all HIV-positive people who are diagnosed, are linked to care, are taking antiretroviral treatment and have undetectable HIV RNA, in eight European and high-income countries: the United States, the United Kingdom, France, the Netherlands, Denmark, Australia, British Columbia (Canada) and Georgia. MATERIALS AND METHODS: For each country, the number of people in five key stages of the HIV treatment cascade was collected: 1. HIV infected, 2. Known to be HIV positive, 3. Linked to care, 4. Taking antiretroviral treatment, and 5. Having undetectable HIV RNA. Estimates were extracted from national reports (1-3), the UNAIDS database, conference proceedings (4) and peer-reviewed articles (5-7). The quality of the estimates and reporting methods were assessed individually for each country, with selection criteria such as availability of nationwide database and routinely collected data. Treatment cascades were constructed using estimates from 2010 to 2012. RESULTS: As shown in Table 1, the percentage of all infected people with undetectable HIV RNA ranged from 20% in Georgia to 59% in Denmark. Of the high-income countries, the United States has the lowest percentage of individuals with undetectable viral load (25% to median 52%), associated with the highest HIV incidence rate (15.30 per 100,000 to median 6.07 per 100,000). The pattern of the cascades differed between countries: in the United States, there is a fall from 66% to 33% (-33%) between linkage to care and start of antiretroviral treatment. However, in Georgia, the greatest loss in continuum was zat diagnosis, with 48% of undiagnosed HIV-positive individuals. CONCLUSIONS: There are great disparities among European and high-income countries in the percentage of HIV-positive individual with undetectable HIV RNA. Furthermore, the treatment cascades show different key break points, underlying inequalities in HIV care between countries.
Authors: Bohdan Nosyk; Julio S G Montaner; Guillaume Colley; Viviane D Lima; Keith Chan; Katherine Heath; Benita Yip; Hasina Samji; Mark Gilbert; Rolando Barrios; Réka Gustafson; Robert S Hogg Journal: Lancet Infect Dis Date: 2013-09-27 Impact factor: 25.071
Authors: H Irene Hall; Emma L Frazier; Philip Rhodes; David R Holtgrave; Carolyn Furlow-Parmley; Tian Tang; Kristen Mahle Gray; Stacy M Cohen; Jonathan Mermin; Jacek Skarbinski Journal: JAMA Intern Med Date: 2013-07-22 Impact factor: 21.873
Authors: Rochelle P Walensky; Ethan D Borre; Linda-Gail Bekker; Stephen C Resch; Emily P Hyle; Robin Wood; Milton C Weinstein; Andrea L Ciaranello; Kenneth A Freedberg; A David Paltiel Journal: Ann Intern Med Date: 2016-05-31 Impact factor: 25.391
Authors: Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Nicole L De La Mata; Limin Mao; John De Wit; Don Smith; Martin Holt; Garrett Prestage; David P Wilson; Kathy Petoumenos Journal: Sex Health Date: 2015-10 Impact factor: 2.706
Authors: Dima Dandachi; Sarah B May; Jessica A Davila; Jeffrey Cully; K Rivet Amico; Michael A Kallen; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Anna V Kuznetsova; Anastasia Y Meylakhs; Yuri A Amirkhanian; Jeffrey A Kelly; Alexey A Yakovlev; Vladimir B Musatov; Anastasia G Amirkhanian Journal: AIDS Behav Date: 2016-10
Authors: Nicholas A Medland; James H McMahon; Eric P F Chow; Julian H Elliott; Jennifer F Hoy; Christopher K Fairley Journal: J Int AIDS Soc Date: 2015-11-30 Impact factor: 5.396
Authors: Thomas M Harmon; Kevin A Fisher; Margaret G McGlynn; John Stover; Mitchell J Warren; Yu Teng; Arne Näveke Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240